U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008196) titled 'Telitacicept for the Treatment of Refractory RA' on May 26.
Brief Summary: This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis (RA)
Intervention:
DRUG: Telitacicept
Telitacicept 160mg qw subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chinese SLE Treatment And Research Group
Information provided by (Responsible Party): Xinping Tian, Chinese SLE Treatment And Research Group
Published by HT Digital Content Servic...